Amicus Therapeutics (FRA:AM6) Net Income (Continuing Operations) : €-26.6 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Amicus Therapeutics's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was €-20.1 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was €-26.6 Mil.

Amicus Therapeutics Net Income (Continuing Operations) Historical Data

The historical data trend for Amicus Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Net Income (Continuing Operations) Chart

Amicus Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-227.57

-221.66

-223.32

-139.00

-53.58

Amicus Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-44.55	-14.58	-6.06	14.08	-20.06

Amicus Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.6 Mil.

Amicus Therapeutics (FRA:AM6) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Amicus Therapeutics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (FRA:AM6) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

FOLD:USA 0HF9:UK

Address

47 Hulfish Street, Princeton, NJ, USA, 08542

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines